argenx SE
XBRU:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
XBRU:ARGX
Watchlist
Price: 582.6 EUR 3.15% Market Closed
Market Cap: 34.8B EUR
Have any thoughts about
argenx SE?
Write Note

argenx SE
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

argenx SE
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
argenx SE
XBRU:ARGX
Cash Taxes Paid
$12.8m
CAGR 3-Years
-5%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Cash Taxes Paid
$14.5m
CAGR 3-Years
300%
CAGR 5-Years
63%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Cash Taxes Paid
-€195k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Cash Taxes Paid
$2.8m
CAGR 3-Years
59%
CAGR 5-Years
35%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

argenx SE
Glance View

Market Cap
34.8B EUR
Industry
Biotechnology

Argenx SE is an innovative biopharmaceutical company that focuses on developing antibody therapies to address severe autoimmune diseases and cancers. Founded in 2008 and headquartered in the Netherlands, Argenx utilizes its proprietary antibody engineering platform, known as the "Differentiated Antibody Platform," to discover and advance therapies with the potential to provide significant benefits over existing treatments. Their lead product, efgartigimod, has garnered attention for its ability to modulate the immune system and effectively reduce the debilitating symptoms of autoimmune conditions like myasthenia gravis. With a growing pipeline that promises to expand the company's reach into additional therapeutic areas, Argenx is positioned as a key player in the healthcare sector, making it an attractive opportunity for investors looking for growth within a dynamic industry. Argenx's commitment to innovation is further underscored by its strong international presence, with collaborations and partnerships that enhance its research capabilities and market access. The company's financial health is bolstered by strategic funding initiatives, including significant collaborations with larger pharmaceutical firms, which provide not only capital but also expertise and resources to accelerate development. As Argenx continues to advance its clinical programs and receive regulatory approvals, its ability to deliver transformative therapies presents a compelling narrative of growth and potential profitability. For investors, Argenx stands out as a forward-thinking enterprise that embodies the principles of disciplined investment through sustainable innovation and long-term value creation.

ARGX Intrinsic Value
591.95 EUR
Undervaluation 2%
Intrinsic Value
Price

See Also

What is argenx SE's Cash Taxes Paid?
Cash Taxes Paid
12.8m USD

Based on the financial report for Jun 30, 2024, argenx SE's Cash Taxes Paid amounts to 12.8m USD.

What is argenx SE's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
56%

Over the last year, the Cash Taxes Paid growth was -67%. The average annual Cash Taxes Paid growth rates for argenx SE have been -5% over the past three years , 56% over the past five years .

Back to Top